Pharming Group Statistics

Total Valuation

Pharming Group has a market cap or net worth of EUR 509.53 million. The enterprise value is 455.84 million.

Market Cap	509.53M
Enterprise Value	455.84M

Important Dates

The next estimated earnings date is Thursday, May 8, 2025.

Earnings Date	May 8, 2025
Ex-Dividend Date	n/a

Share Statistics

Pharming Group has 683.93 million shares outstanding. The number of shares has increased by 2.18% in one year.

Current Share Class	n/a
Shares Outstanding	683.93M
Shares Change (YoY)	+2.18%
Shares Change (QoQ)	+43.13%
Owned by Insiders (%)	2.08%
Owned by Institutions (%)	6.17%
Float	649.07M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.77
PB Ratio	2.39
P/TBV Ratio	3.30
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 97.57, with an EV/FCF ratio of -182.57.

EV / Earnings	-39.86
EV / Sales	1.59
EV / EBITDA	97.57
EV / EBIT	n/a
EV / FCF	-182.57

Financial Position

The company has a current ratio of 3.77, with a Debt / Equity ratio of 0.51.

Current Ratio	3.77
Quick Ratio	2.95
Debt / Equity	0.51
Debt / EBITDA	17.02
Debt / FCF	-43.45
Interest Coverage	-0.41

Financial Efficiency

Return on equity (ROE) is -5.38% and return on invested capital (ROIC) is -0.62%.

Return on Equity (ROE)	-5.38%
Return on Assets (ROA)	-0.52%
Return on Invested Capital (ROIC)	-0.62%
Return on Capital Employed (ROCE)	-1.10%
Revenue Per Employee	710,558
Profits Per Employee	-28,310
Employee Count	404
Asset Turnover	0.69
Inventory Turnover	0.63

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -18.94% in the last 52 weeks. The beta is 0.60, so Pharming Group's price volatility has been lower than the market average.

Beta (5Y)	0.60
52-Week Price Change	-18.94%
50-Day Moving Average	0.79
200-Day Moving Average	0.78
Relative Strength Index (RSI)	47.75
Average Volume (20 Days)	6,078,865

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Pharming Group had revenue of EUR 287.07 million and -11.44 million in losses. Loss per share was -0.02.

Revenue	287.07M
Gross Profit	252.87M
Operating Income	-3.47M
Pretax Income	-8.20M
Net Income	-11.44M
EBITDA	3.11M
EBIT	-3.47M
Loss Per Share	-0.02

Full Income Statement

Balance Sheet

The company has 162.17 million in cash and 108.48 million in debt, giving a net cash position of 53.68 million or 0.08 per share.

Cash & Cash Equivalents	162.17M
Total Debt	108.48M
Net Cash	53.68M
Net Cash Per Share	0.08
Equity (Book Value)	213.52M
Book Value Per Share	0.31
Working Capital	197.66M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -1.73 million and capital expenditures -763,061, giving a free cash flow of -2.50 million.

Operating Cash Flow	-1.73M
Capital Expenditures	-763,061
Free Cash Flow	-2.50M
FCF Per Share	-0.00

Full Cash Flow Statement

Margins

Gross margin is 88.09%, with operating and profit margins of -1.21% and -3.98%.

Gross Margin	88.09%
Operating Margin	-1.21%
Pretax Margin	-2.86%
Profit Margin	-3.98%
EBITDA Margin	1.08%
EBIT Margin	-1.21%
FCF Margin	n/a

Dividends & Yields

Pharming Group does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2.18%
Shareholder Yield	-2.18%
Earnings Yield	-2.24%
FCF Yield	-0.49%

Stock Splits

The last stock split was on March 5, 2013. It was a reverse split with a ratio of 0.1.

Last Split Date	Mar 5, 2013
Split Type	Reverse
Split Ratio	0.1

Scores

Pharming Group has an Altman Z-Score of 2.43. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.43
Piotroski F-Score	n/a